Skip to Content


Zachary Brennan, quoting Rachel E. Sachs (Academic Fellow Alumna)
Regulatory Affairs Professionals Society
January 13, 2017

Read the Full Article

From the article:

Several praised the move to delay the final guidance, particularly as a new administration and Congress work with FDA and the Centers for Medicare & Medicaid Services (CMS) to come up with a new way of regulating LDTs.

Rachel Sachs, a law professor at Washington University in St. Louis, told Focus: “I have been very impressed with the collaborative spirit demonstrated by the FDA and CMS under the leadership of Commissioners [Rob] Califf and [Andy] Slavitt. The discussion in this paper of FDA/CMS collaboration is just one of many recent examples of collaboration between the agencies in ways that have potential to make the process of innovation and regulation more predictable and efficient.” [...]

Read the full article here.

Read the Full Article

Tags

bioethics   biotechnology   fda   health law policy   pharmaceuticals   rachel sachs   regulation